Skip to main content

Advertisement

SpringerLink
Log in

Allogeneic Hematopoietic Stem Cell Transplantation: Does It Have a Place in Treating Hodgkin Lymphoma?

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Although the majority of patients with Hodgkin lymphoma achieve sustained remission with frontline treatment, there is still a subset of patients with much less favorable prognosis. The current standard of care for Hodgkin lymphoma patients with relapsed or refractory disease is autologous stem cell transplantation. However, no randomized trial has compared autologous stem cell transplantation with allogeneic stem cell transplantation prospectively, and most studies comparing allogeneic stem cell transplantation with historical controls of autologous stem cell transplantation use a myeloablative conditioning reference group. With the more frequent use of reduced-intensity conditioning transplantation in recent studies, the role for allogeneic stem cell transplantation in Hodgkin lymphoma patients is being redefined. In contrast to other types of lymphomas, Hodgkin lymphoma patients are younger at diagnosis, which makes a curative strategy such as allogeneic stem cell transplantation particularly appealing. This review examines the role of allogeneic stem cell transplantation in Hodgkin lymphoma by looking at both retrospective and prospective analyses in the era of reduced-intensity conditioning transplantation, donor lymphocyte infusions, and biologically based treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Meyer RM, Gospodarowicz MK, Connors JM, et al.: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005, 23:4634–4642.

    Article  CAS  PubMed  Google Scholar 

  2. Bonadonna G, Bonfante V, Viviani S, et al.: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 2004, 22:2835–2841.

    Article  PubMed  Google Scholar 

  3. Duggan DB, Petroni GR, Johnson JL, et al.: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003, 21:607–614.

    Article  CAS  PubMed  Google Scholar 

  4. Gobbi PG, Levis A, Chisesi T, et al.: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005, 23:9198–9207.

    Article  CAS  PubMed  Google Scholar 

  5. Linch DC, Winfield D, Goldstone AH, et al.: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993, 341:1051–1054.

    Article  CAS  PubMed  Google Scholar 

  6. Schmitz N, Pfistner B, Sextro M, et al.: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002, 359:2065–2071.

    Article  CAS  PubMed  Google Scholar 

  7. Vose JM, Bierman PJ, Anderson JR, et al.: Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992, 80:2142–2148.

    CAS  PubMed  Google Scholar 

  8. Varterasian M, Ratanatharathorn V, Uberti JP, et al.: Clinical course and outcome of patients with Hodgkin’s disease who progress after autologous transplantation. Leuk Lymphoma 1995, 20:59–65.

    Article  CAS  PubMed  Google Scholar 

  9. Castagna L, Magagnoli M, Balzarotti M, et al.: Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin’s lymphoma: a monocenter prospective study. Am J Hematol 2007, 82:122–127.

    Article  CAS  PubMed  Google Scholar 

  10. Appelbaum FR, Sullivan KM, Thomas ED, et al.: Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin’s disease. J Clin Oncol 1985, 3:1490–1494.

    CAS  PubMed  Google Scholar 

  11. Phillips GL, Wolff SN, Herzig RH, et al.: Treatment of progressive Hodgkin’s disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989, 73:2086–2092.

    CAS  PubMed  Google Scholar 

  12. Jones RJ, Piantadosi S, Mann RB, et al.: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 1990, 8:527–537.

    CAS  PubMed  Google Scholar 

  13. Anderson JE, Litzow MR, Appelbaum FR, et al.: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 1993, 11:2342–2350.

    CAS  PubMed  Google Scholar 

  14. Milpied N, Fielding AK, Pearce RM, et al.: Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996, 14:1291–1296.

    CAS  PubMed  Google Scholar 

  15. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31:667–678.

    Article  CAS  PubMed  Google Scholar 

  16. Gajewski JL, Phillips GL, Sobocinski KA, et al.: Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 1996, 14:572–578.

    CAS  PubMed  Google Scholar 

  17. Akpek G, Ambinder RF, Piantadosi S, et al.: Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 2001, 19:4314–4321.

    CAS  PubMed  Google Scholar 

  18. Bonadonna G, Viviani S, Bonfante V, et al.: Survival in Hodgkin’s disease patients—report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005, 41:998–1006.

    Article  PubMed  Google Scholar 

  19. Sirohi B, Cunningham D, Powles R, et al.: Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008, 19:1312–1319.

    Article  CAS  PubMed  Google Scholar 

  20. • Sureda A, Robinson S, Canals C, et al.: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26:455–462. This retrospective analysis was the first to compare reduced-intensity conditioning with myeloablative stem cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. The results demonstrated nearly twice the relapse incidence in the reduced-intensity conditioning group. However, the 5-year overall survival was significantly higher in the reduced-intensity conditioning group, likely because of the lower 1-year nonrelapse mortality.

    Article  CAS  PubMed  Google Scholar 

  21. • Robinson SP, Sureda A, Canals C, et al.: Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009, 94:230–238. This retrospective analysis attempted to predict factors that determine post-transplant outcome following reduced-intensity conditioning transplantation for Hodgkin lymphoma. In multivariate analysis, patients who received fewer lines of chemotherapy and those in complete remission had significantly lower rates of disease progression than patients with refractory disease at the time of reduced-intensity conditioning. Patients with a good performance status, in a complete remission, or with chemosensitive disease had significantly better progression-free survival and overall survival.

    Article  PubMed  Google Scholar 

  22. Devetten MP, Hari PN, Carreras J, et al.: Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009, 15:109–117.

    Article  PubMed  Google Scholar 

  23. Peggs KS, Hunter A, Chopra R, et al.: Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005, 365:1934–1941.

    Article  PubMed  Google Scholar 

  24. Alvarez I, Sureda A, Caballero MD, et al.: Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006, 12:172–183.

    Article  PubMed  Google Scholar 

  25. Anderlini P, Saliba R, Acholonu S, et al.: Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005, 35:943–951.

    Article  CAS  PubMed  Google Scholar 

  26. Anderlini P, Saliba R, Acholonu S, et al.: Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008, 93:257–264.

    Article  CAS  PubMed  Google Scholar 

  27. Todisco M: Low-grade non-Hodgkin lymphoma at advanced stage: a case successfully treated with cyclophosphamide plus somatostatin, bromocriptine, retinoids, and melatonin. Am J Ther 2007, 14:113–115.

    Article  PubMed  Google Scholar 

  28. Majhail NS, Weisdorf DJ, Wagner JE, et al.: Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 2006, 107:3804–3807.

    Article  CAS  PubMed  Google Scholar 

  29. Burroughs LM, O’Donnell PV, Sandmaier BM, et al.: Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:1279–1287.

    Article  PubMed  Google Scholar 

  30. Castagna L, Sarina B, Todisco E, et al.: Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. Biol Blood Marrow Transplant 2009, 15:432–438.

    Article  CAS  PubMed  Google Scholar 

  31. Thomson KJ, Peggs KS, Smith P, et al.: Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008, 41:765–770.

    Article  CAS  PubMed  Google Scholar 

  32. • Sarina B, Castagna L, Farina L, et al.: Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010, 115:3671–3677. A retrospective analysis was performed in 185 Hodgkin lymphoma patients who had HLA typing performed immediately after failed autologous stem cell transplantation to compare allogeneic stem cell transplantation versus conventional treatment in patients with relapsed or refractory Hodgkin lymphoma. In an intent-to-treat analysis, 4-year progression-free survival and overall survival were significantly better in the donor group (P < 0.001).

    Article  CAS  PubMed  Google Scholar 

  33. Peggs KS, Sureda A, Qian W, et al.: Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007, 139:70–80.

    Article  CAS  PubMed  Google Scholar 

  34. Sureda A, Canals C, Arranz R, et al.: Allogeneic stem cell transplantation after reduced intensity conditioning (RIC-allo) in patients with relapsed or refractory Hodgkin’s lymphoma (HL). Final analysis of the HDR-Allo protocol—a prospective clinical trial by the Grupo Espanol de Linfomas / Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 658.

  35. Josting A, Rueffer U, Franklin J, et al.: Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000, 96:1280–1286.

    CAS  PubMed  Google Scholar 

  36. David KA, Mauro L, Evens AM: Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. Curr Treat Options Oncol 2007, 8:352–374.

    Article  PubMed  Google Scholar 

  37. Josting A, Franklin J, May M, et al.: New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2002, 20:221–230.

    Article  PubMed  Google Scholar 

  38. Jabbour E, Hosing C, Ayers G, et al.: Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007, 109:2481–2489.

    Article  PubMed  Google Scholar 

  39. Castagna L, Bramanti S, Balzarotti M, et al.: Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009, 145:369–372.

    Article  CAS  PubMed  Google Scholar 

  40. Klimm B, Schnell R, Diehl V, Engert A: Current treatment and immunotherapy of Hodgkin’s lymphoma. Haematologica 2005, 90:1680–1692.

    CAS  PubMed  Google Scholar 

  41. Schnell R, Dietlein M, Staak JO, et al.: Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005, 23:4669–4678.

    Article  CAS  PubMed  Google Scholar 

  42. Bartlett NL, Younes A, Carabasi MH, et al.: A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008, 111:1848–1854.

    Article  CAS  PubMed  Google Scholar 

  43. Forero-Torres A, Leonard JP, Younes A, et al.: A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009, 146:171–179.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10—Hatfield CRC, Room 3-3121, Bethesda, MD, 20892-1203, USA

    Rachel B. Salit

  2. Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Building 10—Hatfield CRC, Room 4-3140, Bethesda, MD, 20892-1203, USA

    Michael R. Bishop & Steven Z. Pavletic

Authors
  1. Rachel B. Salit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael R. Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven Z. Pavletic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachel B. Salit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salit, R.B., Bishop, M.R. & Pavletic, S.Z. Allogeneic Hematopoietic Stem Cell Transplantation: Does It Have a Place in Treating Hodgkin Lymphoma?. Curr Hematol Malig Rep 5, 229–238 (2010). https://doi.org/10.1007/s11899-010-0065-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-010-0065-7

Keywords

Search

Navigation